By VETTAPHARMA reporter – Derek Roche: Sanofi reported that Biogen has joined accelRare, a free rare disease pre-diagnostic platform developed by Sanofi in collaboration with 13 French rare disease healthcare networks and French startup Medvir, marking an expansion of efforts to reduce diagnostic delays for patients living with rare diseases in France.
The initiative addresses a significant public health challenge in France, where nearly 3 million people are living with a rare disease and more than half remain without a precise diagnosis. Patients wait an average of nearly four years to receive a diagnosis, while some remain undiagnosed for more than a decade.
Available free of charge to physicians, accelRare is designed to support the early identification of suspected rare diseases. The platform combines a database validated by experts from 13 rare disease healthcare networks with Medvir’s pre-diagnostic technology to help clinicians identify potential conditions and refer patients more rapidly to appropriate specialist centers.
The platform currently covers more than 310 rare diseases. Since its launch in 2024, accelRare has supported more than 7,000 pre-diagnoses and has achieved a physician user satisfaction score of 4.54 out of 5.
Under the collaboration, Biogen will promote accelRare through its healthcare professional network to strengthen the pre-diagnosis of selected rare diseases, including Friedreich’s ataxia. The companies also plan to expand the platform’s algorithm by incorporating Biogen’s expertise and specialist network, increasing the number of rare diseases supported, particularly conditions where delayed diagnosis may significantly affect patient outcomes.
For patients, the collaboration aims to shorten the diagnostic journey that often delays access to specialist care and appropriate treatment. Earlier identification of rare diseases may help reduce missed opportunities for intervention and improve disease management.
Commercially, the partnership reflects a growing trend toward ecosystem-based approaches in rare diseases, bringing together pharmaceutical companies, healthcare networks, and technology developers to improve disease recognition and patient referral pathways. The addition of Biogen broadens industry participation in accelRare and supports Sanofi’s strategy of expanding collaborative rare disease initiatives.
Quick FAQs
What Is the Drug/Product/Asset?
accelRare is a free digital pre-diagnostic platform for rare diseases developed by Sanofi, 13 French rare disease healthcare networks, and Medvir. It is designed to help physicians identify suspected rare diseases and refer patients to appropriate specialist centers.
What Happened?
Biogen joined the accelRare initiative in France. The company will help promote the platform among healthcare professionals and contribute expertise to expand its rare disease coverage and diagnostic capabilities.
What Is the Study/Trial?
No clinical study or trial was reported in the announcement. The news concerns a collaboration to expand the accelRare rare disease pre-diagnostic platform and improve identification of rare disease patients.
What Is the Disease Condition?
Rare diseases affect nearly 3 million people in France. More than half of affected individuals lack a precise diagnosis, and many experience prolonged diagnostic delays before reaching specialist care.
What Were the Key Results?
The platform currently supports more than 310 rare diseases, has facilitated over 7,000 pre-diagnoses since its 2024 launch, and has achieved a physician satisfaction score of 4.54/5. Biogen’s participation is expected to expand disease coverage and strengthen diagnostic capabilities.
Why Is This Important?
The collaboration aims to reduce diagnostic delays for rare disease patients, enabling earlier referral and management. Strategically, it expands industry collaboration around rare disease diagnosis and strengthens the reach and capabilities of the accelRare platform.
